Uncategorized

Avalyn plots $182M IPO; WHO prequalifies Novartis’ malaria drug

Published

2 weeks ago

on

Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public offering …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version